PA HB 2749: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.
PA HB 2749 proposes amendments to the Controlled Substance, Drug, Device and Cosmetic Act regarding drug overdose medication, but the excerpt is empty, so specific changes are unknown.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 26, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmaceutical manufacturers, including branded, generic, API, and compounding outsourcing facilities operating in Pennsylvania. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified; bill is in early legislative stage.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The bill would amend the Controlled Substance, Drug, Device and Cosmetic Act to address drug overdose medication, but the specific provisions are not yet available.
Who it affects
Pharmaceutical manufacturers, including branded, generic, API, and compounding outsourcing facilities operating in Pennsylvania.
What you must do
Monitor the bill's progress and review the full text when available to assess potential impacts on manufacturing and distribution practices.
Deadline
Not specified; bill is in early legislative stage.
Source: https://www.palegis.us/legislation/bills
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
- Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV
- US-CONGRESS BILLS-119hr10133ih: Fair Prescription Pricing Act of 2026